Trial Search Results

Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetic profile of RGI-2001 in patients undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT), with radiation or non-radiation myeloablative preparative treatment.

RGI-2001 is an investigational drug (not yet approved by the Food and Drug Administration). RGI-2001modulates (alters) the immune system and may help the donor immune system adjust to your body tissues. RGI-2001 has the potential to reduce the risk of acute graft versus host disease. This is the first study of RGI-2001 in humans.

Stanford is currently not accepting patients for this trial.

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Physician Referrals
Not Recruiting